Key Takeaways
- Legacy business under pressure, battery pivot funded: Organic revenue grew 24% but missed its ₹150 crore/quarter potential, while the inorganic segment halved on lithium-price normalization. The ₹253 crore preferential allotment closed in November, de-risking the balance sheet for the battery capex cycle ahead.
- Battery capacity plan doubled again: Electrolyte salt capacity target raised to 4,000 MT and electrolyte to 32,000 MT, with a new greenfield site now planned. The capex envelope has expanded to an estimated ₹900–₹1,100 crore, spread over the next seven to eight quarters.
- Customer qualification is the gating item: Trial production has begun, but final approvals from two large customers are still pending, and one customer's technology partner is unwilling to share its recipe. Mitsubishi is actively helping to convince customers to adopt its recipe instead.
- FY24 revenue guidance looks out of reach: The first half delivered ~₹335 crore; hitting the ₹800 crore full-year target would require a run rate management says is "very high" and unlikely before Q4, when battery revenue is expected to begin.
- What to watch next quarter: Whether the Mitsubishi design freeze in December unlocks a firm capex number, any progress on customer recipe agreements, and whether the promised pharma recovery actually materializes in Q4.
Battery Business Build-Out
- Capacity scale-up re-planned: The electrolyte salt plant has been expanded from 1,000 MT to 2,000 MT at the existing site, with a further 3,000 MT now planned at a new greenfield site, taking total salt capacity to 4,000 MT. Electrolyte capacity moves from 10,000 MT to 32,000 MT, of which 2,000 MT is own-technology and 30,000 MT uses MUIS technology.
- Capex efficiency argument: Management chose to scale directly to 30,000 MT because the incremental capex per tonne falls sharply at larger scale, improving competitiveness. The total capex estimate has risen to ₹900–₹1,100 crore, roughly two to two-and-a-half times the earlier ₹450 crore plan, and will be deployed over the remaining two quarters of FY24, all of FY25, and two to three quarters of FY26.
- Greenfield site timeline: The dedicated battery-materials site is targeted for commissioning by calendar year 2025, or Q2/Q3 FY26, aligning with the expected demand ramp from three to four giga-scale customers.
- Trial production underway: One section of the 400 MTPA lithium electrolyte salts and additives capacity has begun trial production; the remaining section is in final checks. Stabilization is expected by December, with customer approvals for salts anticipated in Q4 FY24.
- Electrolyte sales start: The 2,000 MT own-technology electrolyte line is being installed in Q4; management expects electrolyte sales to begin by Q4 FY24 or Q1 FY25.
Harin Kanani: "we felt that instead of 10,000 tonnes, when we go to 30,000 MT, the capex does not become three times, right? There is a significant saving when we do further scale-up. So by doing that our capex efficiency per tonne improves. And therefore, our ability to be more competitive improves."
Customer Qualification & Go-to-Market
- Two large customers in evaluation: Both have evaluated samples and are working with their respective technology partners for final approvals. One customer's technology partner is unwilling to share its recipe, creating a bottleneck.
- Mitsubishi as recipe enabler: Mitsubishi is approaching customers directly to convince them to use its recipe, and together with Neogen is trying to demonstrate the advantages. The final technical support and recipe agreement with Mitsubishi is still being negotiated.
- Recipe flexibility model: When a customer has a specific cell design, Neogen gathers the information, consults Mitsubishi, and Mitsubishi recommends the best-fit recipe from its portfolio. This makes the Mitsubishi agreement critical to unlocking multiple customer relationships.
- Geographic demand pull: The U.S. requires non-China electrolyte salt by 2025, and demand inquiries are coming from Japan, Korea, Europe, and the U.S. Management noted that what was originally "plan B" — being a non-China supplier — has become "almost like plan A."
- IRA-compliant supply chain: Electrolyte salts can be made entirely China-free; lithium has been sourced outside China for 30 years, and suppliers are ready for long-term agreements with minimum quantity guarantees. Solvents have some China dependency, but Indian partners have plans to build capacity in two to three years, and Neogen can purify technical-grade solvent to battery grade.
- Domestic competition limited: Management sees no significant other players for electrolytes beyond Neogen and a few listed companies that have announced plans. On Chinese competitors, the view is that they would need to set up a plant in India to compete effectively, which is difficult in the current geopolitical environment.
Harin Kanani: "Almost all geographies are very keen to have a non-China Electrolyte salt supplier. So what was our plan B is becoming almost like plan A."
Legacy Business: Quarter Performance
- Organic Chemicals grew 24% to ₹124 crore, driven by incremental gains from recent capacity expansion, contribution from BuLi Chem, and stable demand for key products. However, this fell short of the ₹150 crore/quarter potential because bromine and other raw material prices declined, and lower demand kept utilization below full.
- Inorganic Chemicals declined 21% to ₹39 crore, entirely due to the normalization of lithium prices from historically high levels in the same quarter last year. Compared to the FY22 Q2 base of ₹22 crore, the segment has nearly doubled, indicating underlying volume growth.
- Volume growth was healthy in organic: Management stated volume growth was more than 24% in the organic segment despite significant raw material price declines, though it declined to provide an exact volume percentage, citing constantly changing product mix.
- EBITDA rose 7% to ₹25.9 crore, helped by a better product mix and rationalization of key input and raw material costs. PAT fell 20% to ₹7.9 crore, weighed down by higher finance costs and depreciation from ongoing capex. The recent preferential allotment will be used to repay strategic debt, reducing finance costs in the near term.
- BuLi Chem stabilized quickly: The acquired business broke even in its first full quarter despite the absence of demand from its largest legacy customers, adding revenue from the first quarter itself. Employee costs jumped partly because BuLi Chem's 50 employees were included for a full quarter versus only one month in Q1, and partly due to annual increments.
Demand Environment & Headwinds
- External pressures persistent: Inventory reduction by customers, continuous dumping by China, deceleration in developed markets, and Middle East conflict driving crude-linked raw material price volatility all weighed on the quarter. The company is partially insulated by its diverse product range and exposure to non-discretionary end-markets like agrochemicals and pharmaceuticals.
- Working capital strained: The last six months have been very volatile, with demand much lower than expected, hurting plans to improve working capital. Operating cash flow was negative in the first half of last year and turned positive in the second half; management aims for a similar improvement this year but cautioned that conditions remain volatile.
- Pharma recovery expected in Q4: Most industry participants expect pharmaceuticals to start improving from Q4 of the current financial year. Some signs of customer interest are visible, but it is too early to call it a sustained recovery.
- FY24 revenue target at risk: The first six months delivered approximately ₹335 crore. To reach the ₹800 crore full-year target, the required run rate for the remaining two quarters is very high. Q3 is not expected to show a large jump, and while Q4 will see battery revenue begin, management acknowledged the target will be difficult to achieve.
Technology & Competitive Position
- Solid-state batteries not a near-term threat: Management cited industry veterans who see solid-state becoming a significant play only after 2030, with large-scale adoption seven to ten years away. Liquid electrolyte will remain necessary for all battery types requiring a liquid medium, including sodium-ion, lithium-ion, and flow chemistry.
- Skills are transferable: Neogen's core competencies in purity, moisture control, packaging, transport, and performance testing are applicable across battery chemistries. The company plans to begin building solid-state capabilities in parallel and expects to be ready in a couple of years rather than decades.
- Capacity scaling will be gated by technology watch: When scaling beyond the initial 30,000 MT — from 30 to 50, from 50 to 70, and so on — management will evaluate at each step how long liquid electrolyte demand is likely to be sustainable versus the pace of solid-state adoption.
- EV adoption assumption: Management uses 30% EV penetration in India by 2030 as a base case, which translates to roughly 150 GWh of battery capacity and 150,000 MT of electrolyte demand. Even if penetration reaches only 25–27%, the impact is small because the base is near zero.
Harin Kanani: "scientists, be it industry veterans, none of them see solid-state becoming a significant play before 2030."
Capital Allocation & Returns Framework
- Funding discipline: The target debt-equity ratio remains 1.25x. Management is "very sure" it does not want to take on new risk and will evaluate raising more funds or exploring partner funding if the ratio approaches that threshold.
- ROCE is the primary metric for battery: Management declined to provide per-tonne gross profit or EBITDA figures, arguing that percentage margins are misleading because sales realization moves with the lithium price index. The stated target is a pre-tax ROCE upward of 20%, with pricing modeled to achieve that threshold.
- Employee cost target: On a stable basis, employee costs are expected to settle at 7–8% of revenue. The current quarter's jump was driven by the full-quarter inclusion of BuLi Chem staff and annual increments.
- Capex clarity pending: The exact capex number cannot be finalized until Mitsubishi completes its design work, expected in December. Management expects to provide clarity before the February earnings call.
Harin Kanani: "I think this is a business where ROE and ROCE, are going to be the key factors. We would like ROCE to be upward of 20%. We like to model and try to get prices of ROCE above 20%."
Guidance & Commitments
| Commitment | Specifics | Timeline |
|---|---|---|
| Electrolyte salt trial stabilization | Phase 1 trial production to stabilize; Phase 2 ready by end of December | December 2023 |
| Electrolyte salt customer approvals | Begin receiving approvals for salts | Q4 FY24 |
| Electrolyte sales start | 2,000 MT own-technology line installed and sales begin | Q4 FY24 or Q1 FY25 |
| Mitsubishi design freeze & capex clarity | Exact capex number to be provided once Mitsubishi finishes design | December 2023 / before February call |
| Greenfield site operational | 30,000 MT electrolyte and 3,000 MT salt capacity commissioned | Calendar year 2025 (Q2/Q3 FY26) |
| Total battery capex deployment | ₹900–₹1,100 crore spent across remaining FY24, FY25, and two to three quarters of FY26 | Second half of FY26 |
| Debt-equity ceiling | Will evaluate raising funds or partner options if ratio approaches 1.25x | Ongoing |
| Battery business ROCE target | Pre-tax ROCE upward of 20% | At commercialization |
Key Metrics
| Metric | Q2 FY24 |
|---|---|
| Consolidated revenue | ₹161.7 cr, +9% YoY |
| Organic Chemicals revenue | ₹124 cr, +24% YoY |
| Inorganic Chemicals revenue | ₹39 cr, -21% YoY |
| Domestic revenue mix | 69% of total revenue |
| Export revenue mix | 31% of total revenue |
| EBITDA | ₹25.9 cr, +7% YoY |
| PAT | ₹7.9 cr, -20% YoY |
| FY24 revenue guidance | ₹800 cr at ~18% EBITDA margin, looks difficult to achieve; H1 FY24 revenue was ~₹335 cr |
| Organic Chemicals installed capacity | 463 m³ as on date; additional 29 m³ expected by end of FY24 |
| Inorganic Chemicals installed capacity | 39 m³ as on date, including 15 m³ reactor capacity added till March 2023 |
| Lithium Electrolyte Salts trial production | 400 MTPA capacity, one section commenced trial production |
| Electrolyte Salts capacity target | 4,000 MT total (1,000 MT existing site + 3,000 MT greenfield), up from 2,000 MT earlier plan |
| Electrolyte capacity target | 32,000 MT total (2,000 MT own technology + 30,000 MT MUIS technology), up from 10,000 MT earlier plan |
| Battery chemicals capex estimate | ₹900–₹1,100 cr, 2 to 2.5 times the earlier ₹450 cr plan, spread over 7–8 quarters ending H2 FY26 |
| Preferential allotment raised | ₹253 cr on 1st November 2023 |
| Target debt-equity ratio | 1.25 |
| ROCE target for battery chemicals | 20%+ pre-tax |